Simcere Pharmaceutical Group Limited (FRA:S2P)

Market Cap	3.48B
Revenue (ttm)	844.70M
Net Income (ttm)	104.62M
Shares Out	n/a
EPS (ttm)	0.04
PE Ratio	33.25
Forward PE	22.82
Dividend	0.02 (1.53%)
Ex-Dividend Date	Jun 18, 2025

Volume	n/a
Average Volume	n/a
Open	1.290
Previous Close	1.270
Day's Range	1.290 - 1.290
52-Week Range	0.800 - 1.600
Beta	n/a
RSI	38.87
Earnings Date	Mar 20, 2026

About FRA:S2P

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 6,584
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: S2P

Financial Performance

In 2024, FRA:S2P's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY